Comparative effectiveness of ribociclib plus fulvestrant (RIB plus FUL) versus palbociclib plus letrozole (PAL plus LET) as first-line (1L) treatment (Tx) of HR+/HER2L advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC)
Fasching P, Delea T, Lu YS, Deboer R, Hurvitz SA, Moynahan A, Chandiwana D, Lanoue B, Hu H, Thuerigen A, O'Shaughnessy J (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S377-S378
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1016/j.annonc.2020.08.432
Authors with CRIS profile
Involved external institutions
Novartis AG
Switzerland (CH)
Royal Melbourne Hospital (RMH)
Australia (AU)
Baylor University (BU)
United States (USA) (US)
National Taiwan University Hospital (NTUH) / 國立台灣大學醫學院附設醫院
Taiwan (TW)
University of California Los Angeles (UCLA)
United States (USA) (US)
Switzerland (CH)
Royal Melbourne Hospital (RMH)
Australia (AU)
Baylor University (BU)
United States (USA) (US)
National Taiwan University Hospital (NTUH) / 國立台灣大學醫學院附設醫院
Taiwan (TW)
University of California Los Angeles (UCLA)
United States (USA) (US)
How to cite
APA:
Fasching, P., Delea, T., Lu, Y.-S., Deboer, R., Hurvitz, S.A., Moynahan, A.,... O'Shaughnessy, J. (2020). Comparative effectiveness of ribociclib plus fulvestrant (RIB plus FUL) versus palbociclib plus letrozole (PAL plus LET) as first-line (1L) treatment (Tx) of HR+/HER2L advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC). In ANNALS OF ONCOLOGY (pp. S377-S378). AMSTERDAM: ELSEVIER.
MLA:
Fasching, Peter, et al. "Comparative effectiveness of ribociclib plus fulvestrant (RIB plus FUL) versus palbociclib plus letrozole (PAL plus LET) as first-line (1L) treatment (Tx) of HR+/HER2L advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC)." Proceedings of the ESMO Virtual Congress AMSTERDAM: ELSEVIER, 2020. S377-S378.
BibTeX: Download